L-Carnitine for PCOS: The Trials, the Retractions, and What Still Holds

Does L-Carnitine Help You Get Pregnant With PCOS?

Three of the trials that built L-carnitine’s reputation as a clomiphene-resistance fix have been retracted or placed under a journal’s expression of concern since 2023. That is the single most important fact in this article, and it is rarely mentioned anywhere it is sold. The story starts with a 2014 trial reporting that adding L-carnitine to clomiphene lifted cumulative pregnancy rates from 5.8% to 51.5% in 170 women — a genuinely dramatic number that made its way into supplement marketing copy for a decade. Two similarly striking Egyptian trials followed in 2019, one pairing L-carnitine with metformin, one comparing it head-to-head against NAC.

Independent reviewers examining the 2019 retraction found that tables across two of these papers, published in different journals under the same corresponding author, contained an “implausible” pattern of identical digits, and that neither the baseline p-values nor the reported outcomes could be reproduced from the data provided. The 2014 trial’s own retraction notice cites the same concern; the 2019 metformin-combination trial was retracted separately in 2024 on the same grounds, and the 2016 weight-loss trial — a different research group, covered in its own section below — has carried an editorial expression of concern since 2023. None of the four trials above is reliable evidence today. This is not a reason to assume L-carnitine does nothing for fertility or weight — it is a reason to say plainly that the specific evidence usually cited for those claims no longer exists.

What Do the Independent Fertility Trials Actually Show?

Two more recent, independently run trials tested L-carnitine directly against pregnancy and IVF outcomes in PCOS and found no benefit on either. An 83-woman trial added 3,000 mg/day of L-carnitine to a GnRH-antagonist frozen-embryo-transfer protocol and found oocyte maturity, fertilisation, and implantation, chemical, and clinical pregnancy rates all statistically comparable to placebo — the only difference reaching significance was a higher oestradiol level on the day of trigger, a laboratory value with no established clinical meaning on its own. A 110-woman trial gave 3,000 mg/day of L-carnitine for six weeks before an antagonist-protocol IVF/ICSI cycle and reached the same conclusion in its title: “doesn’t improve the outcomes of IVF/ICSI cycle.” Both trials, notably, still found L-carnitine lowered weight, fasting glucose, insulin, and cholesterol — the metabolic effect held even where the fertility effect did not.

A 2025 systematic review pooling eight randomized trials and 1,046 participants did find a significant pooled improvement in chemical and clinical pregnancy rates, ovulation rate, and endometrial thickness, searching the literature through March 2024. Read that finding with the table above in view: its search window overlaps directly with trials on this exact question that were retracted in 2023, and with one retracted only in December 2024 — after the review’s own search cutoff, meaning it would have been treated as standing literature at the time the pooling was done. A meta-analysis is only as sound as the trials that feed it, and this is precisely the situation Section 1 of this article describes: a positive pooled fertility signal sitting on a literature base that, piece by piece, has been found unreliable.

Does L-Carnitine Help With Weight or Insulin Resistance in PCOS?

Two 12-week trials at 1,000 mg/day of plain L-carnitine, run independently of the retracted group, found a genuine insulin-sensitivity effect but no clinically meaningful change in weight or lipids. The first, in 62 overweight or obese women with PCOS, found significant improvement in fasting insulin, HOMA-IR, and the QUICKI insulin-sensitivity index compared with placebo, with no significant change in SHBG, fasting glucose, or any lipid measured. The second, the same trial population assessed for a different set of outcomes, found no significant difference from placebo in liver fat content or any of four calculated cardiometabolic risk indices after accounting for waist circumference. A separate trial tested acetyl-L-carnitine — a different compound, covered below — as an add-on to metformin and pioglitazone in 147 women, and found the three-drug combination lowered insulin and raised adiponectin more than metformin and pioglitazone alone, with regular menstrual cycles returning in 97.2% of the combination group against 12.9% of the two-drug group.

A 2022 meta-analysis pooling nine trials and 995 women found L-carnitine improved fasting glucose, LDL, total cholesterol, and triglycerides with low-to-moderate certainty. Read this one with the same caution as the fertility review above: its search ran from inception to June 2021, a window that includes at least four of the trials named in Table 1 above, later retracted or placed under concern — meaning a meaningful share of the trials feeding this pooled lipid and glucose estimate are no longer standing evidence, a limitation the review itself could not have addressed at the time it was written.

L-Carnitine vs Acetyl-L-Carnitine vs L-Carnitine L-Tartrate: Are They Interchangeable?

Three related compounds share the word “carnitine,” and only two of them have been tested in PCOS at all. Plain L-carnitine — the form in Sangouni’s, Sheida’s, and Hafezi’s trials above — is the base molecule, typically dosed at 1,000 to 3,000 mg/day in the trials reviewed here. Acetyl-L-carnitine (ALC), used in Tauqir’s trial at 3,000 mg/day, carries an acetyl group that improves its ability to cross the blood-brain barrier, which is why it is more often studied for nerve and cognitive outcomes elsewhere in the literature — its one PCOS trial tested it only as an add-on to two prescription drugs, not alone. L-carnitine L-tartrate (LCLT) is the third form, sold heavily for exercise recovery and muscle soreness — and it does not appear in a single PCOS trial identified for this article. If a product on a shelf is labelled LCLT, none of the dose or outcome data above transfers to it directly.

The Research Group Behind Several of These Trials

One author, appearing on five of the L-carnitine-and-PCOS trials identified for this article, carries a track record across her wider body of work that this site treats as a standing caution rather than a reason to dismiss every paper she has touched: roughly 35 retractions across approximately 549 PubMed-indexed papers, an order of magnitude above background rates for biomedical research. Two of her five L-carnitine PCOS papers are the 2016 weight-loss trial now under expression of concern in Table 1. The remaining three — on carotid intima-media thickness, and two on carnitine paired with chromium for weight and mental-health outcomes — have not been retracted or flagged as of this writing, but a clean record today is not the same as independent confirmation, and none of their specific findings has been replicated by a different research group. Where this article draws on that remaining body of work, it says so; where it does not cite it at all, that is deliberate rather than an oversight.

Is L-Carnitine a Cardiovascular Risk? The TMAO Question

Gut bacteria convert dietary L-carnitine into trimethylamine, which the liver oxidises into trimethylamine N-oxide (TMAO) — a compound that a landmark 2013 study linked to accelerated atherosclerosis in mice and to elevated cardiovascular risk in omnivorous humans, independent of traditional risk factors. That study was not conducted in PCOS, and no PCOS trial listed above measured TMAO as an outcome — a real and, for this specific question, unfilled gap, not a reason to dismiss the concern. Separately from supplementation entirely, women with PCOS already run higher baseline TMAO than matched controls: one case-control study found significantly elevated plasma TMAO in women with PCOS without hyperandrogenism compared with 27 age- and BMI-matched non-PCOS women, and a separate study found the same pattern tied to gut microbiota composition. PCOS already carries elevated cardiometabolic risk on its own, which is why this overlap is worth naming rather than ignoring.

The picture complicates rather than resolves in one direction, though. A 2025 study in a mouse model of PCOS found that TMAO supplementation actually improved oocyte quality rather than worsening reproductive markers — a rodent finding, in the opposite direction from the cardiovascular-risk story, and evidence that TMAO’s biology is not simply “more is worse” across every tissue and every outcome. No trial has measured whether L-carnitine supplementation itself raises circulating TMAO in women with PCOS specifically, whether that would matter clinically at PCOS-trial doses, or how it interacts with PCOS’s already-elevated baseline. This is genuinely an open question, not a settled harm and not a non-issue — treat it as one more factor, alongside the fertility-evidence picture above, in deciding whether a 3,000 mg/day supplement earns a place in your routine.

Who This Will Not Help

If you are taking L-carnitine specifically to improve your odds of ovulating or conceiving on clomiphene, the trials that evidence rested on are retracted, and the two independent trials that remain found no fertility benefit at any dose tested. If your goal is weight loss, the two best-designed independent trials found no significant change in weight, lipids, or liver fat at 1,000 mg/day over 12 weeks — the metabolic benefit that does show up consistently is improved insulin sensitivity, a narrower claim than “helps you lose weight.” And if a cardiovascular risk factor already runs in your family, the TMAO question above is unresolved specifically for L-carnitine supplementation in PCOS — worth raising with a clinician rather than either ignoring or assuming the worst.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Nothing about the L-carnitine evidence above changes with the name — this article uses PCOS because that is still what most readers search. The 2023 international PCOS guideline that underpins most of this site’s dosing pages does not address L-carnitine at all, in either direction — it is outside what that document reviewed, the same gap that shows up for several other supplements on this site.

Your Next Step

If a clinician has raised L-carnitine as a clomiphene add-on, ask directly whether the recommendation rests on the retracted 2014–2019 trials or on the independent evidence in Table 2 — the honest answer changes what to expect. Clomiphene-resistant PCOS: next steps covers the options with a currently standing evidence base. For the insulin-resistance mechanism these trials are actually testing, insulin resistance and PCOS lays out what HOMA-IR is measuring and why it matters, and metformin for PCOS covers the prescription option with the larger trial base behind the same mechanism. If it’s the energy-metabolism angle that drew you here rather than fertility, creatine and PCOS is the other amino-acid-derived supplement on this site with its own, separate trial record.